focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
No need to worry!
https://www.youtube.com/watch?v=qN30JMLOd60
Maybe with news circulating further, the SP will pick up
https://www.uktech.news/news/investment-news/motion-capture-oxford-metrics-revenue-20231205
Write up here………..
https://www.voxmarkets.co.uk/articles/oxford-metrics-drivers-to-growth-and-catalysts-for-rerating-cab8960/
I found Berms 21:15 yesterday very interesting:
1) Genmab have advised that they intend to take SC129 into clinical trials.
2) Genmab are interested in another mAb.
So not only is there a live chance that SC129 may in time result in revenue to fuel advancement of other products in the pipeline, industry giant Genmab provide further endorsement of Scancell’s work, by saying another mAb is interesting them.
A Wow for me!
Yeah I think linked to this convo about new news, is what I said yesterday about not yet having MHRA approval for iSCIB+.
When I read that section yesterday, it came across to me as a delay caused by not supplying MHRA, with what they should have known they would ask for before approval could be granted.
That was however just my interpretation and I may be being harsh given I don’t know any MHRA correspondence details, or dates of.
Regardless, it now needs to come quickly so as not to delay further imo.
11th December rapidly approaching. We already know from the recent Trading Update……
“Revenue and adjusted operating profit expected to increase by c.13%, with a good mix of organic and acquired growth”
Positive expectations set then, that the Company’s strategy is working well and they are delivering on their promises. It will be interesting to see the detail and of course the future outlook. Not long to wait.
The one slight disappointment for me in todays RNS, was that MHRA approval is not yet in the bag. I was really hoping for confirmation of that this year. A formality? Maybe but a green light would have added weight to todays RNS - imo.
And this, a different one on Proactive this morning……..
https://www.proactiveinvestors.co.uk/companies/news/220600/scancell-focuses-on-development-of-two-critical-cancer-fighting-assets-220600.html